--- title: "Beyond the Molecule: Why Your Teams Will Decide Who Wins Pharma’s Innovation Race" description: Discover why your teams and culture are crucial for driving innovation in the pharma industry amidst rising costs, regulatory pressure, and intense competition. image: https://blog.breakthroughglobal.com/hubfs/toon-lambrechts-P04Fd8Ln0gQ-unsplash.jpg --- [![dark-logoi-hs](https://blog.breakthroughglobal.com/hubfs/dark-logoi-hs.svg "dark-logoi-hs")](https://blog.breakthroughglobal.com/) - [Home](https://breakthroughglobal.com/) - [About](https://breakthroughglobal.com/about) - [Breakthrough Model](https://breakthroughglobal.com/why-us) - [Our Story](https://breakthroughglobal.com/our-story) - [Our Clients](https://breakthroughglobal.com/results) - [Resources](https://breakthroughglobal.com/podcasts) Show submenu for Resources - [Insights](https://blog.breakthroughglobal.com/) - [Podcasts](https://breakthroughglobal.com/podcasts) - [FAQs](https://breakthroughglobal.com/faqs) - [Contact us](https://breakthroughglobal.com/contact) - [Home](https://breakthroughglobal.com/) - [About](https://breakthroughglobal.com/about) - [Breakthrough Model](https://breakthroughglobal.com/why-us) - [Our Story](https://breakthroughglobal.com/our-story) - [Our Clients](https://breakthroughglobal.com/results) - [Resources](https://breakthroughglobal.com/podcasts) Show submenu for Resources - [Insights](https://blog.breakthroughglobal.com/) - [Podcasts](https://breakthroughglobal.com/podcasts) - [FAQs](https://breakthroughglobal.com/faqs) - [Contact us](https://breakthroughglobal.com/contact) [Login](https://breakthroughglobal.fuseuniversal.com/users/sign_in) [Insights](https://blog.breakthroughglobal.com/blog) / Beyond the Molecule: Why Your Teams Will Decide Who Wins Pharma’s Innovation Race # Beyond the Molecule: Why Your Teams Will Decide Who Wins Pharma’s Innovation Race **Date:** 24.11.25 **Read:** 6 mins **Share:** [mailto:?body=https://blog.breakthroughglobal.com/beyond-the-molecule-why-your-teams-will-decide-who-wins-pharmas-innovation-race](mailto:?body=https://blog.breakthroughglobal.com/beyond-the-molecule-why-your-teams-will-decide-who-wins-pharmas-innovation-race) #### Contents [Introduction](https://blog.breakthroughglobal.com/beyond-the-molecule-why-your-teams-will-decide-who-wins-pharmas-innovation-race#Introduction) [The Crunch: Innovate Faster, Under a Brighter Spotlight](https://blog.breakthroughglobal.com/beyond-the-molecule-why-your-teams-will-decide-who-wins-pharmas-innovation-race#the-crunch) [Why This is a People Problem As Much As a Pipeline Problem](https://blog.breakthroughglobal.com/beyond-the-molecule-why-your-teams-will-decide-who-wins-pharmas-innovation-race#people-problem) [Practical Moves for Pharma Leaders](https://blog.breakthroughglobal.com/beyond-the-molecule-why-your-teams-will-decide-who-wins-pharmas-innovation-race#practical-moves) [Conclusion](https://blog.breakthroughglobal.com/beyond-the-molecule-why-your-teams-will-decide-who-wins-pharmas-innovation-race#conclusion) ![](https://blog.breakthroughglobal.com/hubfs/toon-lambrechts-P04Fd8Ln0gQ-unsplash.jpg) If you work in pharma right now, you’re probably feeling squeezed from every direction. On one hand, there’s relentless pressure to constantly innovate and bring new drugs and therapies to market faster. On the other hand, regulatory scrutiny, pricing pressure and competition are all intensifying at once. [McKinsey’s latest work on life sciences](https://www.mckinsey.com/industries/life-sciences/our-insights/reimagining-life-science-enterprises-with-agentic-ai) and recent [PwC analysis](https://www.pwc.com/gx/en/about/analyst-relations/2023/idc-life-science-r-d-strategic-consulting-2023.html) summed it up bluntly: pharma is under pressure to create new products while R&D costs rise, regulatory expectations toughen, and competitors multiply. In an earlier Breakthrough blog, **“**[**Your Org Chart is a Cage**](https://blog.breakthroughglobal.com/your-org-chart-is-a-cage-how-siloed-thinking-is-sabotaging-your-pharma-and-med-tech-breakthroughs)**”**, we argued that the real bottleneck isn’t usually science, it’s how leaders align, decide and execute under pressure. This piece builds on that and makes a simple claim. **Your people and culture are not a “soft” concern. They’re your sharpest levers for managing risk, speeding decisions and staying competitive.** ## **1. The Crunch: Innovate Faster, Under a Brighter Spotlight** The core challenge is easy to describe and hard to solve. You have to: - **Fill the pipeline** with credible new molecules and modalities. - **Navigate complex clinical, regulatory and access pathways**. - **Protect margins** in a world of generics, biosimilars and new entrants. - **Do all of this WHILE your teams are already stretched**. A [Cytiva analysis](https://www.cytivalifesciences.com/en/us/behind-biopharma/stories/solving-the-rd-productivity-puzzle-10002) estimates the average pre-tax cost of each new prescription drug at around $2.6bn, with approvals under pressure and productivity still a concern. At the same time, global deals and growth strategies are running into tougher oversight. Regulatory scrutiny has already delayed some larger pharma deals, forcing dealmakers to be more cautious and [adding friction to portfolio bets](https://www.pwc.com/gx/en/services/deals/trends/h1-2023/health-industries.html). So the stakes are high, timelines are tight, and the room for error is narrow. Technology, AI and smarter operating models are part of the answer as McKinsey points to “[Pharma 4.0](https://www.mckinsey.com/industries/life-sciences/our-insights/future-of-pharma-operations)” style operations with advanced analytics, digital connectivity and new treatment modalities reshaping the landscape. **But technology doesn’t use itself. And this is where the people function becomes central**. ## **2. Why This is a People Problem As Much As a Pipeline Problem** When we talk with pharma leaders, 3 human themes show up again and again as the biggest risks, and the biggest opportunities. **a) Quality Culture is Now a Competitive Edge** Regulators like the [MHRA](http://mhrainspectorate.blog.gov.uk/) have been clear for years that “quality culture” is the foundation for product quality and continuity of supply. Industry articles on quality culture in pharma highlight the same pattern: - When quality is owned only by QA, the organisation becomes reactive - According to [World Pharma Today](https://www.worldpharmatoday.com/articles/quality-creates-value-unlocking-quality-culture-as-a-competitive-edge-in-the-pharmaceutical-industry), when quality is owned by *everyone*, deviations fall, audits go better and regulators trust you more. **b) Alignment Beats Heroics** In our **“**[**One Company, One Voice**](https://blog.breakthroughglobal.com/one-company-one-voice)**”** blogpost, we described how fragmented leadership and competing agendas slow decisions in consumer pharma even when strategy is clear. The same dynamic shows up across the wider industry: - Global vs local fights over priorities - Regulatory, medical and commercial teams with conflicting KPIs - Functions optimising their own piece of the puzzle rather than the end-to-end journey. In **“Your Org Chart is a Cage”** we showed how these silos quietly sabotage breakthrough innovation and speed in pharma and med-tech. In a high-scrutiny environment, misalignment is more than a pesky thing. It increases risk as- - More hand-offs mean more chances to miss something in a submission - Slower decisions mean a higher cost of delay for launches - Internal conflict drains the energy you urgently need for patients and markets. [![1-Nov-24-2025-12-09-37-6849-PM](https://143594092.fs1.hubspotusercontent-eu1.net/hub/143594092/hubfs/1-Nov-24-2025-12-09-37-6849-PM.png?width=1200&length=1200&name=1-Nov-24-2025-12-09-37-6849-PM.png)](https://blog.breakthroughglobal.com/one-company-one-voice) [![2-Nov-24-2025-12-09-51-3774-PM](https://143594092.fs1.hubspotusercontent-eu1.net/hub/143594092/hubfs/2-Nov-24-2025-12-09-51-3774-PM.png?width=1200&length=1200&name=2-Nov-24-2025-12-09-51-3774-PM.png)](https://blog.breakthroughglobal.com/your-org-chart-is-a-cage-how-siloed-thinking-is-sabotaging-your-pharma-and-med-tech-breakthroughs)   **c) Burnout & Fear Slow the Very Innovation You Need** Many come into pharma because they care deeply about patients and science. That purpose is powerful,  and can also mask chronic overload. When humans are exhausted and fearful: - They take fewer smart risks - They hide problems instead of surfacing them early - They retreat to their silo because collaboration feels like “just one more thing.” It’s no coincidence that our most-read Breakthrough pieces across sectors are about mindset, time and culture – from **“**[**Why Slow is the New Fast**](https://blog.breakthroughglobal.com/why-slow-is-the-new-fast)**”** to **“**[From the Ground Up](https://blog.breakthroughglobal.com/from-the-ground-up-building-a-culture-that-serves-success)**.”** Pharma is feeling exactly that tension. You need to move faster but the way people are working is often unsustainably intense already. [![1-Nov-24-2025-12-14-44-8883-PM](https://143594092.fs1.hubspotusercontent-eu1.net/hub/143594092/hubfs/1-Nov-24-2025-12-14-44-8883-PM.png?width=1200&length=1200&name=1-Nov-24-2025-12-14-44-8883-PM.png)](https://blog.breakthroughglobal.com/why-slow-is-the-new-fast) [![2-Nov-24-2025-12-15-06-5251-PM](https://143594092.fs1.hubspotusercontent-eu1.net/hub/143594092/hubfs/2-Nov-24-2025-12-15-06-5251-PM.png?width=1200&length=1200&name=2-Nov-24-2025-12-15-06-5251-PM.png)](https://blog.breakthroughglobal.com/from-the-ground-up-building-a-culture-that-serves-success)   ## **3. Practical Moves for Pharma Leaders** So if you’re leading People & Culture, HR or OD in a pharma company, what can you *actually* do? Here are 4 moves we see making a real difference: **1) Translate Strategy into Human Commitments** Don’t stop at “We’ll grow in oncology” or “We’ll lead in immunology” Work with leaders to define a handful of everyday behaviours that make the strategy real, for example: - “We make cross-functional decisions in the room, not by email chains.” - “We treat quality issues as system problems to learn from, not individual blame.” - “We start meetings with the patient impact, not the slide count.” Then bake those commitments into performance conversations and leadership Programmes. **2) Redesign Incentives so the Company Stops Fighting Itself** Wherever possible, give senior leaders shared metrics that cut across functions, such as: - **Time-to-decision** on key portfolio choices. - **Right-first-time** regulatory submissions. - **Patient and HCP experience scores** in launch markets. You will still need functional KPIs,  but when bonuses and recognition reward collective success, people behave differently. **3) Build “Bridge” Talent Deliberately** Identify and grow the people who naturally translate between worlds: - Regulatory leads who can speak “data and tech” - Data scientists who understand clinical nuance - Medical colleagues who can talk easily with commercial teams. Give them rotations, sponsorship and visibility. These connectors are often the ones who quietly keep programmes moving under pressure. **4) Make Time & Attention a Leadership Topic, Not a Personal Problem** In our work, we use tools like *Power Time®* to help leaders design how they spend their energy, not just their hours. For pharma, this might mean: - Resetting decision forums so the real decision-makers are present and meetings are shorter and sharper - Protecting deep work time in R&D and data teams - Being explicit about what will *stop* so that strategic initiatives can land. When leaders treat time as a strategic resource rather than an infinite buffer, people feel permission to focus on what actually matters. ## Conclusion The pressure to develop new drugs and therapies will only increase. Regulatory scrutiny and competition will not ease up. Your differentiator will not be *only* your science, your AI or your deal pipeline. It will be your ability to build a culture where people- - Feel safe to speak up and fix issues early - Move fast together rather than heroically alone - Carry patient impact as the reference point for every decision. **Your people's function is not just “soft stuff.” In today’s pharma, they are your strategy.**   ## Reach out to our team to start a conversation. If you're ready to strengthen your culture, improve collaboration or reduce operational drag, we’d love to talk. [Previous](https://blog.breakthroughglobal.com/niche-to-normal-why-younger-luxury-shoppers-choose-values-over-logos) [Next](https://blog.breakthroughglobal.com/the-ultimate-cultural-makeover) ### Read more of our blogs: [Lessons from the Room: 5 Hard Truths About Closing the AI Value Gap](https://blog.breakthroughglobal.com/lessons-from-the-room) ![](https://blog.breakthroughglobal.com/hubfs/image%20(13)-1.png) 16.06.26 #### Lessons from the Room: 5 Hard Truths About Closing the AI Value Gap On the surface, it appears that every enterprise is effortlessly scaling AI to unlock massive productivity gains. Behind the scenes, however, the conversations reveal a completely... [Read More](https://blog.breakthroughglobal.com/lessons-from-the-room) [Beyond the Firewall: Culture is Your Strongest (or Weakest) Security Asset](https://blog.breakthroughglobal.com/beyond-the-firewall-culture-is-your-strongest-or-weakest-security-asset) ![](https://blog.breakthroughglobal.com/hubfs/Professional%20office%20environment%20showing%20workplace%20silence%20and%20blame%20culture.%20People%20in%20business%20attire%20looking%20hesitant%2c%20avoiding%20eye%20contact%2c%20covering%20mouths%2c%20or%20looking%20down.%20Muted%20corporate%20colors%20with%20tense%20atmosphere.%20Subtle%20body%20langu.png) 5.06.26 #### Beyond the Firewall: Culture is Your Strongest (or Weakest) Security Asset Here's a question worth sitting with: when did your organisation last update its firewall? Probably recently. When did you last examine whether people actually follow the security... [Read More](https://blog.breakthroughglobal.com/beyond-the-firewall-culture-is-your-strongest-or-weakest-security-asset) [Why a Great AI Strategy Fails at the Middle Management Level](https://blog.breakthroughglobal.com/why-a-great-ai-strategy-fails-at-the-middle-management-level) ![](https://blog.breakthroughglobal.com/hubfs/mapbox-ZT5v0puBjZI-unsplash.jpg) 8.05.26 #### Why a Great AI Strategy Fails at the Middle Management Level Globally, AI systems have permeated every industry. Executives see a future of streamlined processes, unprecedented growth and trillions in efficiency gains. Leaders, however, report that... [Read More](https://blog.breakthroughglobal.com/why-a-great-ai-strategy-fails-at-the-middle-management-level) [Can You Have Psychological Safety AND High Accountability?](https://blog.breakthroughglobal.com/can-you-have-psychological-safety-and-high-accountability) ![](https://blog.breakthroughglobal.com/hubfs/vitaly-gariev-ZFBrAHDW9P4-unsplash.jpg) 28.04.26 #### Can You Have Psychological Safety AND High Accountability? There’s a quiet debate that organisations are overly prioritising empathy at the expense of progression. The worry among leadership is that by becoming overly concerned with making people... [Read More](https://blog.breakthroughglobal.com/can-you-have-psychological-safety-and-high-accountability) [Why Waiting for Performance Reviews is Costing You Your Best Talent](https://blog.breakthroughglobal.com/april-is-too-late-why-waiting-for-performance-reviews-is-costing-you-your-best-talent) ![System for your Goals](https://blog.breakthroughglobal.com/hubfs/isaac-smith-Ij7h-m4nJ18-unsplash.jpeg) 14.04.26 #### Why Waiting for Performance Reviews is Costing You Your Best Talent Once a year, the annual performance review rises to the top of conversations. Managers prepare for what can feel like a root canal, and employees are bracing for a verdict on work they... [Read More](https://blog.breakthroughglobal.com/april-is-too-late-why-waiting-for-performance-reviews-is-costing-you-your-best-talent) ![footer-logo (1)](https://blog.breakthroughglobal.com/hs-fs/hubfs/footer-logo%20(1).png?width=250&height=127&name=footer-logo%20(1).png "footer-logo (1)") - [Home](https://breakthroughglobal.com/) - [About](https://breakthroughglobal.com/about) - [Clients](https://breakthroughglobal.com/results) - [Insights](https://blog.breakthroughglobal.com/) - [Podcast](https://breakthroughglobal.com/podcasts) - [Contact us](https://breakthroughglobal.com/contact) - [Privacy Policy](https://breakthroughglobal.com/privacy-policy) **Have a general enquiry?** [contact@breakthroughglobal.com](mailto:contact@breakthroughglobal.com) **Want to partner with us?** [partnerships@breakthroughglobal.com](mailto:partnerships@breakthroughglobal.com) [London](https://www.google.com/maps/dir//15+Grape+St,+London+WC2H+8DR/@51.5162566,-0.2079574,12z/data=!4m8!4m7!1m0!1m5!1m1!1s0x4876101d308daa51:0x54412738d2b09eca!2m2!1d-0.1255572!2d51.5162855?entry=ttu&g_ep=EgoyMDI0MTExMy4xIKXMDSoASAFQAw%3D%3D) [Singapore](https://www.google.com/maps/dir/52.822016,-2.097152/breakthrough+global+singapore/@1.9672794,-35.2683656,3z/data=!3m1!4b1!4m9!4m8!1m1!4e1!1m5!1m1!1s0x31da191343eb5b27:0x4f149dbec7913922!2m2!1d103.8458098!2d1.2756998?entry=ttu) ### Sign up to our newsletter and stay up to date with all things Breakthrough ![](https://px.ads.linkedin.com/collect/?pid=7154857&fmt=gif) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Parsha Sharwar", "url" : "https://blog.breakthroughglobal.com/author/parsha-sharwar" }, "dateModified" : "2025-11-25T09:35:39.464Z", "datePublished" : "2025-11-24T12:30:41.000Z", "headline" : "Beyond the Molecule: Why Your Teams Will Decide Who Wins Pharma’s Innovation Race", "image" : [ "https://blog.breakthroughglobal.com/hubfs/toon-lambrechts-P04Fd8Ln0gQ-unsplash.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.breakthroughglobal.com/beyond-the-molecule-why-your-teams-will-decide-who-wins-pharmas-innovation-race", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.breakthroughglobal.com/hubfs/dark-logoi-hs.svg" } } } ```